Posaconazole is a new extended-spectrum triazole that is approved for the prophylaxis
of invasive fungal diseases (IFDs) in severely immunocompromised patients.
1
It has proven efficacy in reducing the incidence of IFDs and deaths from IFDs in
patients with severe graft-versus-host disease (GVHD) post-allogeneic hematopoietic
stem cell transplantation (allo-HSCT) and patients on induction chemotherapy for acute
myeloid leukemia (AML).
Center for drug evaluation and research. Application number: 22-027. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022027s000_LBL.pdf [last accessed 28.09.12].
2
It was licensed in Singapore in 2009, and has been included into the antimicrobial
prophylaxis protocol for AML induction chemotherapy in the National University Cancer
Institute, Singapore (NCIS) as well as for the neutropenic phase of allo-HSCT in NCIS
and the Singapore General Hospital (SGH) since 2010. We present our clinical experience
with posaconazole prophylaxis in these institutions – the only public sector hospitals
offering allo-HSCT and AML induction chemotherapy in Singapore.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Journal of InfectionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
Center for drug evaluation and research. Application number: 22-027. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2006/022027s000_LBL.pdf [last accessed 28.09.12].
- Antifungal prophylaxis during treatment for haematological malignancies: are we there yet?.Br J Haematol. 2011; 153: 681-697
- Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group.Clin Infect Dis. 2008; 46: 1813-1821
- Prevalence of invasive fungal disease in hematological patients at a tertiary university hospital in Singapore.BMC Res Notes. 2011; 4: 42
- Fatal rhizopus pneumonia in allogeneic stem cell transplant patients despite posaconazole prophylaxis: two cases and review of the literature.Biol Blood Marrow Transplant. 2009; 15: 991-995
- Pharmacokinetics of different dosing strategies of oral posaconazole in patients with compromised gastrointestinal function and who are at high risk for invasive fungal infection.Antimicrob Agents Chemother. 2012; 56: 2652-2658
Article info
Publication history
Published online: November 30, 2012
Accepted:
November 24,
2012
Identification
Copyright
© 2012 The British Infection Association. Published by Elsevier Inc. All rights reserved.
